Izotropic Corp. · CSE:IZO
Izotropic — Investor Presentation (2026)
15 slides from Izotropic's investor presentation, 2026
Slide 1: Corporate Presentation
Summer 2026 Corporate Presentation Advanced Imaging. Accessible Care. @IZOTROPIC WWW.IZOCORP.COM in @IZOTROPICCORP OTCQB: IZOZF | CSE: IZO
Slide 2: Disclaimer
Disclaimer This document including links to press releases, presentations, fact sheets, and/or corporate materials including audio and video files either linked or imbedded, may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, project
Slide 3: Company Overview
Compan Overvielt ¢ Izotropic Corporation is a publicly listed medtech company commercializing a dedicated Breast CT imaging system, called IzoView, specifically for adjunctive breast cancer screening in patients with dense breast tissue. ¢ IzoView delivers true 3D imaging without breast compression,
Slide 4: The Market Challenge
The Market Challenge Current Technologies Fail the 50% of Women who have Dense Breasts’. « Mammography and DBT are limited by breast compression that causes tissue overlap and breast imaging artifacts. Mammogram of a “Not Dense” Breast Mammogram of a “Dense Breast” * Mammography misses ~20% of cance
Slide 5: The Global Market Opportunity
GLOBAL $8.69B $7.2B ra.) eee Ses, 2024 2028 2030 2024 2028 2030 The Global Market Opportunity Breast Imaging is a High-Growth, High-Need Market. Breast cancer is the most diagnosed cancer in women globally, with 2.3M+ new cases/year'. * Global breast imaging device market to grow from $5.4B in 2024
Slide 6: Introducing IzoView
———_ e - Introducing “{20View IzoView — Engineered for Today’s Challenges & Tomorrow’s Care Models. ~<
Slide 7: IzoView Breast CT
IzoView Bre No Compression. No delays. Just Answers. « IzoView delivers high-resolution, 360° images of the breast in its natural, uncompressed position, with or without contrast enhancement. * While contrast-enhanced imaging delivers the highest sensitivity, IzoView is also capable of non-contrast
Slide 8: Clinical Performance
crs AIZOTROPIC @ View more breast CT clinical data here Performance ¢ Developed over 2+ decades, over USD $20M spent on building and testing 4 successive breast CT scanners, funded primarily by the NIH. e UC Davis-based clinical trials using prototype devices for academic research purposes have imag
Slide 9: Competitive Positioning
¥ ompetitive IzoView is the only true 3D breast imaging modality specifically focused on dense tissue screening without breast compression. Strategically positioned to address the gap in between DBT and MRI: fast and affordable imaging with high-value imaging data. Designed for outpatient clinics, m
Slide 10: Business Model & Revenue Opportunity
Business Model & Revenue Opportunity A High-Margin, Platform-Based Model with Recurring Revenue. © Capital equipment sales model: target sales price of $500K per unit with high gross margin profile, designed for rapid ROI. * Flexible financing options: Revenue-sharing models and leasing structures s
Slide 11: Intellectual Property
Intellectual Strategic IP Portfolio Secures Long-Term Leaders| « IP protection extending into the 2040s. * Proprietary Al deep machine-learning reconstruction algorithm held as trade secret. « Licensed patents and patents held by the Company covering key clinical and commercial uses, spanning platfo
Slide 12: Regulatory, Commercial & Market Strategy
Regulatory, Commercial & Market Strategy ¢ Designed for rapid adoption in outpatient imaging centers, national cancer programs, and underserved regions. ¢ Aligned with dense breast screening mandates and emerging reimbursement pathways. * Clinical data from planned U.S.-based 3 site clinical study t
Slide 13: Team
JOHN BOONE, PH.D. YOUNES ACHKIRE, PH.D. e ROBERT THAST RALPH PROCEVIAT, CPA | CEO CFO FOUNDER, DIRECTOR COO & LEAD ENGINEER Izotropic’s team includes the original inventors of breast CT, FDA regulatory advisors, and commercialization leaders from GE Healthcare, together mitigating execution and appr
Slide 14: Why Now?
Why Now? Global breast cancer detection is at an inflection point, driven by regulation, awareness, and innovation. * FDA breast density mandates are now in effect, standard imaging often fails these patients. * Global breast imaging device market projected to grow to $8.7B by 2030' (CAGR 8.25%). »*
Slide 15: Izotropic
ww IZOTROPIC LY CORP O Reis Advanced Imaging. Accessible Care. ~ www.IZOCORP.COM CQB: IZOZF | CSE: IZO info@izocorp.com | ir@izocorp.com 1-833-IZO-CORP